|
1
|
Takeuchi H, Miyata H, Gotoh M, Kitagawa Y,
Baba H, Kimura W, Tomita N, Nakagoe T, Shimada M, Sugihara K and
Mori M: A risk model for esophagectomy using data of 5354 patients
included in a Japanese nationwide Web-based database. Ann Surg.
260:259–266. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412.
2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tachimori Y, Ozawa S, Numasaki H,
Fujishiro M, Matsubara H, Oyama T, Shinoda M, Toh Y, Udagawa H and
Uno T: Registration Committee for Esophageal Cancer of the Japan
Esophageal Society. Comprehensive registry of esophageal cancer in
Japan, 2009. Esophagus. 13:110–137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang R, Liu S, Chen B and Xi M: Recent
advances in combination of immunotherapy and chemoradiotherapy for
locally advanced esophageal squamous cell carcinoma. Cancers
(Basel). 14(5168)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kato K, Cho BC, Takahashi M, Okada M, Lin
CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, et al:
Nivolumab versus chemotherapy in patients with advanced oesophageal
squamous cell carcinoma refractory or intolerant to previous
chemotherapy (ATTRACTION-3): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:1506–1517. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L,
Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, et al: Nivolumab
combination therapy in advanced esophageal Squamous-Cell carcinoma.
N Engl J Med. 386:449–462. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kato K, Kojima T, Hara H, Tsuji A, Yasui
H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, et al: First-line
pembrolizumab plus chemotherapy for advanced/metastatic esophageal
cancer: 1-year extended follow-up in the Japanese subgroup of the
phase 3 KEYNOTE-590 study. Esophagus. 21:306–318. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Xue Y, Zhou X, Xue L, Zhou R and Luo J:
The role of pretreatment prognostic nutritional index in esophageal
cancer: A meta-analysis. J Cell Physiol. 234:19655–19662.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang H, Shang X, Ren P, Gong L, Ahmed A,
Ma Z, Ma R, Wu X, Xiao X, Jiang H, et al: The predictive value of a
preoperative systemic immune-inflammation index and prognostic
nutritional index in patients with esophageal squamous cell
carcinoma. J Cell Physiol. 234:1794–802. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wang Y, Chen L, Wu Y, Li P and Che G: The
prognostic value of modified Glasgow prognostic score in patients
with esophageal squamous cell cancer: A Meta-analysis. Nutr Cancer.
72:1146–1154. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sakai M, Sohda M, Saito H, Ubukata Y,
Nakazawa N, Kuriyama K, Hara K, Sano A, Ogata K, Yokobori T, et al:
Comparative analysis of immunoinflammatory and nutritional measures
in surgically resected esophageal cancer: A Single-center
retrospective study. In Vivo. 34:881–887. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ignacio de Ulíbarri J, González-Madroño A,
de Villar NG, González P, González B, Mancha A, Rodríguez F and
Fernández G: CONUT: A tool for controlling nutritional status.
First validation in a hospital population. Nutr Hosp. 20:38–45.
2005.PubMed/NCBI
|
|
13
|
Takagi K, Buettner S, Ijzermans JNM and
Wijnhoven BPL: Systematic review on the controlling nutritional
status (CONUT) score in patients undergoing esophagectomy for
esophageal cancer. Anticancer Res. 40:5343–5349. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Makino T, Nakai S, Momose K, Yamashita K,
Tanaka K, Miyata H, Yamamoto S, Motoori M, Kimura Y, Ushimaru Y, et
al: Efficacy and survival of nivolumab treatment for
recurrent/unresectable esophageal squamous-cell carcinoma:
Real-world clinical data from a large Multi-institutional cohort.
Esophagus. 21:319–327. 2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kosumi K, Baba Y, Hara Y, Wang H, Nomoto
D, Toihata T, Ohuchi M, Harada K, Eto K, Ogawa K, et al: Body
composition and clinical outcomes in esophageal cancer patients
treated with immune checkpoint inhibitors. Ann Surg Oncol.
31:3839–3849. 2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kitagawa Y, Uno T, Oyama T, Kato K, Kato
H, Kawakubo H, Kawamura O, Kusano M, Kuwano H, Takeuchi H, et al:
Esophageal cancer practice guidelines 2017 edited by the Japan
Esophageal Society: Part 1. Esophagus. 16:1–24. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hino C, Lee EW and Yang GY: Harnessing the
abscopal effect for gastrointestinal malignancies in the era of
immunotherapy. J Gastrointest Oncol. 14:1613–1625. 2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lee JH, Kang D, Ahn JS, Guallar E, Cho J
and Lee HY: Obesity paradox in patients with Non-small cell lung
cancer undergoing immune checkpoint inhibitor therapy. J Cachexia
Sarcopenia Muscle. 14:2898–2907. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tanaka T, Narazaki M and Kishimoto T: IL-6
in inflammation, immunity, and disease. Cold Spring Harb Perspect
Biol. 6(a016295)2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shimada H, Nabeya Y, Okazumi S, Matsubara
H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S
and Ochiai T: Elevation of preoperative serum C-reactive protein
level is related to poor prognosis in esophageal squamous cell
carcinoma. J Surg Oncol. 83:248–252. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sektioglu IM, Carretero R, Bulbuc N, Bald
T, Tüting T, Rudensky AY and Hämmerling GJ: Basophils promote tumor
rejection via chemotaxis and infiltration of CD8+ T cells. Cancer
Res. 77:291–302. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kang TG, Park HJ, Moon J, Lee JH and Ha
SJ: Enriching CCL3 in the tumor microenvironment facilitates T cell
Responses and improves the efficacy of Anti-PD-1 therapy. Immune
Netw. 21(e23)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wu C, Qiu Y, Zhang R, Li X, Liang H, Wang
M, Li F, Zhu M, Ye G, Liu H, et al: Association of peripheral
basophils with tumor M2 macrophage infiltration and outcomes of the
anti-PD-1 inhibitor plus chemotherapy combination in advanced
gastric cancer. J Transl Med. 20(386)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rosner S, Kwong E, Shoushtari AN, Friedman
CF, Betof AS, Brady MS, Coit DG, Callahan MK, Wolchok JD, Chapman
PB, et al: Peripheral blood clinical laboratory variables
associated with outcomes following combination nivolumab and
ipilimumab immunotherapy in melanoma. Cancer Med. 7:690–697.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Krizova L, Benesova I, Zemanova P, Spacek
J, Strizova Z, Humlova Z, Mikulova V, Petruzelka L and Vocka M:
Immunophenotyping of peripheral blood in NSCLC patients
discriminates responders to immune checkpoint inhibitors. J Cancer
Res Clin Oncol. 150(99)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
LaMarche NM, Hegde S, Park MD, Maier BB,
Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin
C, et al: An IL-4 signalling axis in bone marrow drives
pro-tumorigenic myelopoiesis. Nature. 625:166–1674. 2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Muller M, Best MG, van der Noort V,
Hiltermann TJN, Niemeijer AN, Post E, Sol N, In 't Veld SGJG,
Nogarede T, Visser L, et al: Blood platelet RNA profiles do not
enable for nivolumab response prediction at baseline in patients
with Non-small cell lung cancer. Tumour Biol. 46 (Suppl):S327–S340.
2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Inoue H, Shiozaki A, Fujiwara H, Konishi
H, Kiuchi J, Ohashi T, Shimizu H, Arita T, Yamamoto Y, Morimura R,
et al: Absolute lymphocyte count and C-reactive protein-albumin
ratio can predict prognosis and adverse events in patients with
recurrent esophageal cancer treated with nivolumab therapy. Oncol
Lett. 24(257)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang H, Lin J, Huang Y and Chen Y: The
systemic Immune-inflammation index as an independent predictor of
survival in patients with locally advanced esophageal squamous cell
carcinoma undergoing neoadjuvant radiotherapy. J Inflamm Res.
17:4575–4586. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Counsilman CE, Jol-van der Zijde CM,
Stevens J, Cransberg K, Bredius RG and Sukhai RN: Pharmacokinetics
of rituximab in a pediatric patient with therapy-resistant
nephrotic syndrome. Pediatr Nephrol. 30:1367–1370. 2015.PubMed/NCBI View Article : Google Scholar
|
